<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 – 11:00</td>
<td>Changing paradigms and future concepts in peripheral interventions</td>
<td>Gunnar Tepe</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dierk Scheinert</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gary Ansel</td>
</tr>
<tr>
<td>10:10 – 10:15</td>
<td>Early look at the VISION Trial: OCT guided atherectomy using Avinger's Pantheris catheter</td>
<td>Arne Schwindt</td>
</tr>
<tr>
<td>10:15 – 10:20</td>
<td>The role of vessel preparation – insights from the Heidelberg PANTHER registry</td>
<td>Erwin Blessing</td>
</tr>
<tr>
<td>10:25 – 10:43</td>
<td>Live case transmission from Leipzig part II</td>
<td></td>
</tr>
<tr>
<td>10:43 – 10:48</td>
<td>Should all stents promote swirling flow?</td>
<td>Thomas Zeller</td>
</tr>
<tr>
<td>10:53 – 11:00</td>
<td>Biodegradable vascular scaffolds – how far have we come?</td>
<td>Iris Baumgartner</td>
</tr>
<tr>
<td>10:48 – 10:53</td>
<td>The TOBA-trial 12 months results with the Tack-device for dissection sealing in the SFA</td>
<td>Marc Bosiers</td>
</tr>
<tr>
<td>10:00 – 10:05</td>
<td>DCB + atherectomy: The ISAR STATH trial results</td>
<td>Massimiliano Fusaro</td>
</tr>
<tr>
<td>10:05 – 10:10</td>
<td>DCB + atherectomy for complex lesions: DEFINITIVE AR – Final data</td>
<td>Gunnar Tepe</td>
</tr>
</tbody>
</table>

We are asking all faculty members to strictly respect the given time limits.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:35 – 09:40</td>
<td>LEVANT II clinical trial: 2-year data</td>
</tr>
<tr>
<td>09:30 – 09:35</td>
<td>In.Pact-SFA clinical trial: Update on 1-year data</td>
</tr>
<tr>
<td>09:40 – 09:45</td>
<td>My take-home messages from LEVANT II and In.Pact SFA – a critical review</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Panel discussion and vote</td>
</tr>
<tr>
<td>10:00 – 11:00</td>
<td>Future prospects for DCB and alternative endovascular concepts</td>
</tr>
<tr>
<td>09:30 – 10:00</td>
<td>Live case transmission from Leipzig part I</td>
</tr>
<tr>
<td>09:30 – 10:00</td>
<td>Drug-coated balloons: Finally proven as the first-line therapy for femoro-popliteal de-novo lesions?</td>
</tr>
</tbody>
</table>

We are asking all faculty members to strictly respect the given time limits.
Tuesday, January 27, 2015

MAIN ARENA 1

13:30 – 15:00  Symposium: DCB setting the stage for standard of care – an evidence-based review
supported with an educational grant from Medtronic
CHARMAN: Erich Minar
MODERATOR: Peter Gaines
Gunnar Tepe
Gary Ansel
Hans Krankenberg
William Gray

14:30 – 14:50  Live case transmission from Cotignola

14:50 – 15:00  IN.PACT role in SFA: Critical overview of modern endovascular therapies
Frank Vermassen

14:20 – 14:30  Are all DCB equal?
William Gray

14:10 – 14:20  DCB and ISR: Insights from FAIR study
Hans Krankenberg

13:40 – 14:00  Live case transmission from Leipzig

14:00 – 14:10  IN.PACT global sub-analysis update: TASC C-D lesions
Gary Ansel

13:30 – 13:40  IN.PACT in fem-pop TASC A-B and diabetics
Gunnar Tepe

We are asking all faculty members to strictly respect the given time limits.
Tuesday, January 27, 2015

MAIN ARENA 1

15:00 – 16:30  **Current concepts and advances for long femoropopliteal lesions and in-stent restenosis**

*CHAIRMAN:*
Tony Das

*MODERATOR:*
Jörn Balzer
Francesco Liistro
Peter Gaines
Marc Bosiers
Sabine Steiner
Michael Werk
Roberto Gandini

15:52 – 16:15  Live case transmission from Leipzig

16:15 – 16:20  Excimer laser atherectomy for in-stent restenosis: Results of the EXCITE trial
Eric Dippel

16:20 – 16:25  The Copa Cabana study: DEB vs. POBA in in-stent restenosis
**Gunnar Tepe**

16:25 – 16:30  The cost economic value of DCB
Konstantinos Katsanos

15:47 – 15:52  The Leipzig experience with DCB, conventional, and interwoven nitinol stents for complex SFA disease
Sabine Steiner

15:42 – 15:47  The endoluminal bypass – the best solution for long lesions and ISR?
Peter Soukas

15:07 – 15:12  After 10,000+ DCB: How has this technology changed our clinical practice for complex SFA lesions?
Andréj Schmidt

15:12 – 15:19  One-year follow-up of the DEBAS STUDY
Patrice Mwipatayi

15:19 – 15:26  Is the combination of DCB and bare metal stents as effective as DES? The BIOLUX 4EVER trial
Marc Bosiers

*We are asking all faculty members to strictly respect the given time limits.*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 15:00 – 15:07 | What works best for long SFA disease? A review of the evidence  
Marc Bosiers |
| 15:26 – 15:42 | Live case transmission from Dendermonde        |

We are asking all faculty members to strictly respect the given time limits.
Thursday, January 29, 2015

DISCUSSION FORUM

12:30 – 13:30  The great debate: Are all DCB equal?
CHAIRMAN:
Michael Jaff
Dierk Scheinert
DISCUSSANT:
Gunnar Tepe
Renu Virmani
Stephan Duda
Marianne Brodmann

13:05 – 13:12  DCB are still a valid option to solve the challenge of BTK vessel patency: Lutonix BTK trials are continuing
Marianne Brodmann

13:12 – 13:30  Discussion and conclusion

12:58 – 13:05  Lessons learned from INPACT.Deep and why we should stay away from DCB for BTK interventions
Erich Minar

12:51 – 12:58  What’s next to come in the drug delivery space: Ongoing DCB programmes
Stephan Duda

12:37 – 12:44  Lacking head-to-head trials comparing different DCB studies is comparing apples and oranges – Results have been substantially affected by trial design

12:44 – 12:51  The relevance of Paclitaxel dose and coating for efficacy and safety
Renu Virmani

12:30 – 12:37  There are clear differences in DCB outcomes in the SFA for various coatings – DCB are not equal!
Gunnar Tepe

We are asking all faculty members to strictly respect the given time limits.